• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing
  3. / Stocks

It's Tough to Weed Through the Data on Tilray

The largest impediment to success for firms like TLRY -- which is expected to report a 27 cent loss per share Tuesday night -- remains federal legalization of marijuana across the U.S.
By STEPHEN GUILFOYLE
Aug 13, 2019 | 11:45 AM EDT
Stocks quotes in this article: NVDA, AMAT, BABA, M, WMT, DDS, JCP, TLRY, CGC, NVS, BUD

On deck. Ninety percent of corporate America has already stepped to the plate. There are still a few higher profile tech names out there. Nvidia ( NVDA) and Applied Materials ( AMAT) come to mind. Several Chinese domiciled firms have yet to report, too, most notably Alibaba ( BABA) .
 
Then there are the retailers. They are coming, and coming in size. Macy's ( M) will lead off on Wednesday morning, then Walmart ( WMT) , Dillard's ( DDS) , and the curiosity that is JC Penney ( JCP)  report. Perhaps overlooked, are a couple of headline level Canadian cannabis producers, Tilray ( TLRY)  is Tuesday night, and Canopy Growth ( CGC)  is on Wednesday. It seems that in the blink of an eye, cannabis went from hot, hot, hot to cold as ice. Let's take a look at Tilray. Shall we?

Tilray at Bat

The Toronto-based cannabis producer will put second-quarter performance to the tape after the second bell. The conference call, which for money-losing operations -- heck, really for everyone in this day and age -- is often more important than results, is scheduled for 5 p.m. ET.
 
Current expectations are for a loss per share of 27 cents on revenue of roughly $40.2 million. The revenue number, if realized, would be good for year-over-year growth of 313%. While the loss would widen significantly from a year ago, at a 27 cent loss, this would be flat sequentially. Whispers out there are for perhaps a penny below consensus. The revenue print will take precedence for investors over the profit/loss, in my opinion.
 
Understand the groundwork. For the full year 2018, revenue across the entire industry amounted to $12.2 billion. Expectations for this year are for roughly $17 billion. Remember that back in 2018, Cowen estimated the global market for cannabis to size out around $50 billion. Cowen analyst Vivien Azer, by the way, is considered a leader in the industry of cannabis.
 
The largest impediment to success for firms like Tilray remains federal legalization of marijuana across the U.S. A total of 33 states as well as the District of Columbia allow legalized medical use cannabis, and 11 of those also allow some recreational use.
 
Once cannabis is legalized, it becomes difficult to imagine that U.S. domiciled firms will not emerge to compete with their Canadian counterparts that will obviously have a significant head start.
 
This is one reason why partnerships -- or even equity stakes -- with larger U.S. firms are a key focus for the industry at this point. Tilray, it appears, has a competitive advantage here. Currently, Tilray has a deal in place with Sandoz, a Novartis ( NVS)  subsidiary, to distribute non-combustible product where legal. Tilray also has a significant deal -- worth about $100 million -- in place with Anheuser-Busch InBev ( BUD) to create non-alcoholic beverages infused with CBD or THC or both, where legal.
 

The Chart: A Tough Technical Read

 
While the daily MACD and Relative Strength apparently offer us little in the way of technical analysis for this company, it may be important that the shares appear to be taking the 50-day simple moving average amid Tuesday's broader-based rally.
 
Understand that by most metrics, these shares are, even though down for the year, over-valued. Forget about a price-to-earnings ratio, these shares are trading at 73-times trailing sales, but "only" 23-times expected sales.
 
This data, though will change by Tuesday evening.
 
An investor is not truly able to analyze this name fundamentally. This is speculative. That understood, I would not enter into an equity stake with out doing something either to hedge the position, or to reduce net basis. Traders who decide to go this route, will do it without me. This is not a condemnation. I am happy with my book the way it is. That said, a trader interested in getting in ahead of the numbers, but also interested in controlling net basis could....
 

Trade Plan

-Purchase 100 shares of TLRY at or close to the last sale of $43.15.
 
-Sell one Sept. 20 TLRY $50 call for roughly $1.87.
 
-Sell one Sept. 20 TLRY $35 put for roughly $1.37.

Net Basis: $39.91
 
Note: Profit on such a trade would be capped by a potential sale at $50 in a month's time for a profit of 25.3%. Worst case, the trader is exposed to increased equity. In the event of such a sell-off, the trader would be left long 200 shares upon Sept. 20 expiration with a net basis of $37.46 with the shares trading below $35. 

(Nvidia is a holding in Jim Cramer's Action Alerts PLUS member club. Want to be alerted before Jim Cramer buys or sells NVDA? Learn more now.)

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Stephen Guilfoyle was long on NVDA equity.
 
TAGS: Earnings | Investing | Stocks | Cannabis

More from Stocks

Costco: Are We Witnessing a Bull Trap?

Bruce Kamich
Oct 3, 2023 1:08 PM EDT

When one of the last holdouts of the S&P 500 turns down the selloff is in full gear.

Chasing Alpha With Alphabet

Ed Ponsi
Oct 3, 2023 12:35 PM EDT

I'm not the only one who likes the tech behemoth. Bill Ackman believes Alphabet will be a leader in AI for years to come.

Looking for Capitulation? Don't Be Fooled by Minor Market Bounces

James "Rev Shark" DePorre
Oct 3, 2023 11:45 AM EDT

The market is trying to discount the impact of higher rates, but it's extremely difficult.

The Trickiest Stock in the Market

Stephen Guilfoyle
Oct 3, 2023 11:15 AM EDT

There's a lot to like about this name, but a lot that also sows the seeds of caution.

Is Akamai Facing a Downside Reversal?

Bruce Kamich
Oct 3, 2023 10:30 AM EDT

Or, will the stock keep climbing? Let's check.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 12:13 PM EDT BRUCE KAMICH

    8 Trading Rules from T. T. Hoyne

    You just read the header for this missive and prob...
  • 08:42 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    How Elite Traders Make Big Profits
  • 02:58 PM EDT BRUCE KAMICH

    Classic Trading Rules From Bernard Baruch

    Bernard Baruch listed the rules (below) in his aut...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2023 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login